170 related articles for article (PubMed ID: 27673440)
61. Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study.
Fassas A; Buffels R; Anagnostopoulos A; Gacos E; Vadikolia C; Haloudis P; Kaloyannidis P
Br J Haematol; 2002 Feb; 116(2):308-15. PubMed ID: 11841431
[TBL] [Abstract][Full Text] [Related]
62. Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia.
Berman E; McBride M; Lin S; Menedez-Botet C; Tong W
Leukemia; 1995 Oct; 9(10):1631-7. PubMed ID: 7564501
[TBL] [Abstract][Full Text] [Related]
63. Phase I study of temozolomide in relapsed/refractory acute leukemia.
Seiter K; Liu D; Loughran T; Siddiqui A; Baskind P; Ahmed T
J Clin Oncol; 2002 Aug; 20(15):3249-53. PubMed ID: 12149298
[TBL] [Abstract][Full Text] [Related]
64. Benefit Mixed with Caution for Buparlisib.
Cancer Discov; 2017 Feb; 7(2):121. PubMed ID: 27986714
[TBL] [Abstract][Full Text] [Related]
65. Phase II study of BKM120 in patients with advanced esophageal squamous cell carcinoma (EPOC1303).
Kojima T; Kato K; Hara H; Takahashi S; Muro K; Nishina T; Wakabayashi M; Nomura S; Sato A; Ohtsu A; Doi T
Esophagus; 2022 Oct; 19(4):702-710. PubMed ID: 35904643
[TBL] [Abstract][Full Text] [Related]
66. Preclinical and clinical evaluation of Buparlisib (BKM120) in recurrent/refractory Central Nervous System Lymphoma.
Grommes C; Pentsova E; Schaff LR; Nolan CP; Kaley T; Reiner AS; Panageas KS; Mellinghoff IK
Leuk Lymphoma; 2023 Sep; 64(9):1545-1553. PubMed ID: 37317993
[TBL] [Abstract][Full Text] [Related]
67. A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study.
Kirschbaum MH; Frankel P; Synold TW; Xie Z; Yen Y; Popplewell L; Chen R; Aljitawi O; Tuscano JM; Chan KK; Newman EM
Leuk Lymphoma; 2016 Oct; 57(10):2307-14. PubMed ID: 26895565
[TBL] [Abstract][Full Text] [Related]
68. The adolescent and young adult with cancer: state of the art-- acute leukemias.
Gramatges MM; Rabin KR
Curr Oncol Rep; 2013 Aug; 15(4):317-24. PubMed ID: 23757222
[TBL] [Abstract][Full Text] [Related]
69. Oral ipriflavone (7-isopropoxy-isoflavone) treatment for elderly patients with resistant acute leukemias.
Pagano L; Teofili L; Mele L; Piantelli M; Ranelletti FO; Equitani F; Larocca LM; Leone G
Ann Oncol; 1999 Jan; 10(1):124-5. PubMed ID: 10076734
[No Abstract] [Full Text] [Related]
70. Buparlisib is a brain penetrable pan-PI3K inhibitor.
de Gooijer MC; Zhang P; Buil LCM; Çitirikkaya CH; Thota N; Beijnen JH; van Tellingen O
Sci Rep; 2018 Jul; 8(1):10784. PubMed ID: 30018387
[TBL] [Abstract][Full Text] [Related]
71. Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials.
Clarke PA; Workman P
J Clin Oncol; 2012 Jan; 30(3):331-3. PubMed ID: 22162582
[No Abstract] [Full Text] [Related]
72. The use of buparlisib as a radiosentisiser: What about toxicity?
van Dam PA
Eur J Cancer; 2019 Sep; 119():194-195. PubMed ID: 31427119
[No Abstract] [Full Text] [Related]
73. Reply to 'The use of buparlisib as a radiosensitiser: What about toxicity?'.
McGowan DR; Skwarski M; Higgins GS
Eur J Cancer; 2019 Sep; 119():196-197. PubMed ID: 31427118
[No Abstract] [Full Text] [Related]
74. Buparlisib-and the continued quest for the ideal cure.
Worden FP
Lancet Oncol; 2017 Mar; 18(3):273-274. PubMed ID: 28131787
[No Abstract] [Full Text] [Related]
75. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease.
Issa GC; Kantarjian HM; Yin CC; Qiao W; Ravandi F; Thomas D; Short NJ; Sasaki K; Garcia-Manero G; Kadia TM; Cortes JE; Daver N; Borthakur G; Jain N; Konopleva M; Khouri I; Kebriaei P; Champlin RE; Pierce S; O'Brien SM; Jabbour E
Cancer; 2017 Feb; 123(3):459-467. PubMed ID: 27696391
[TBL] [Abstract][Full Text] [Related]
76. Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial.
Sclafani F; Kim TY; Cunningham D; Kim TW; Tabernero J; Schmoll HJ; Roh JK; Kim SY; Park YS; Guren TK; Hawkes E; Clarke SJ; Ferry D; Frodin JE; Ayers M; Nebozhyn M; Peckitt C; Loboda A; Watkins DJ
Int J Cancer; 2017 Jan; 140(2):431-439. PubMed ID: 27681944
[TBL] [Abstract][Full Text] [Related]
77. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial.
San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Schlossman RL; Hou J; Moreau P; Lonial S; Lee JH; Einsele H; Sopala M; Bengoudifa BR; Binlich F; Richardson PG
Lancet Haematol; 2016 Nov; 3(11):e506-e515. PubMed ID: 27751707
[TBL] [Abstract][Full Text] [Related]
78. The History of the Follicular Variant of Papillary Thyroid Carcinoma.
Tallini G; Tuttle RM; Ghossein RA
J Clin Endocrinol Metab; 2017 Jan; 102(1):15-22. PubMed ID: 27732333
[TBL] [Abstract][Full Text] [Related]
79. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.
Ravaud A; Motzer RJ; Pandha HS; George DJ; Pantuck AJ; Patel A; Chang YH; Escudier B; Donskov F; Magheli A; Carteni G; Laguerre B; Tomczak P; Breza J; Gerletti P; Lechuga M; Lin X; Martini JF; Ramaswamy K; Casey M; Staehler M; Patard JJ;
N Engl J Med; 2016 Dec; 375(23):2246-2254. PubMed ID: 27718781
[TBL] [Abstract][Full Text] [Related]
80. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
Hortobagyi GN; Stemmer SM; Burris HA; Yap YS; Sonke GS; Paluch-Shimon S; Campone M; Blackwell KL; André F; Winer EP; Janni W; Verma S; Conte P; Arteaga CL; Cameron DA; Petrakova K; Hart LL; Villanueva C; Chan A; Jakobsen E; Nusch A; Burdaeva O; Grischke EM; Alba E; Wist E; Marschner N; Favret AM; Yardley D; Bachelot T; Tseng LM; Blau S; Xuan F; Souami F; Miller M; Germa C; Hirawat S; O'Shaughnessy J
N Engl J Med; 2016 Nov; 375(18):1738-1748. PubMed ID: 27717303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
